title: Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial.
abstract: Canine parvoviral enteritis continues to cause significant morbidity and mortality in dogs worldwide, and efficacious antiviral therapies are lacking. The present trial was aimed at evaluating the therapeutic efficacy of a recombinant feline interferon (type omega) preparation in the treatment of parvoviral enteritis in dogs. A double-blind, placebo-controlled challenge trial was performed in beagle pups (8-9 weeks); clinical signs, body weight, hematologic parameters, and mortality were monitored for a period of 14 days after challenge. Fourteen animals were inoculated with virulent canine parvovirus; 10 animals that developed clinical signs thereby meeting the inclusion criteria were admitted to the treatment phase in two randomly selected groups (placebo and IFN) of equal size. The IFN group received daily intravenous injections of rFeIFN-omega (2.5 MU/kg) for three consecutive days. The placebo group received daily injections of saline without IFN. Both groups of animals received individual supportive treatment consisting of adjusted diet and electrolyte solution. All five dogs in the placebo group developed fulminating enteritis with typical clinical signs and died within 10 days post-inoculation (or 6 days post-treatment). In the IFN-treated group, one animal died on day 2 after the treatment was started, whereas the other four dogs survived the challenge and gradually recovered. Our data confirm that the rFeIFN-omega can exert a significant therapeutic effect on dogs with parvoviral enteritis by improving clinical signs and reducing mortality.
authors.affiliation: Biological R&D, Laboratory Virbac, B.P. 27, 06511 Carros Cedex, France.
authors.forename: Virginie
authors.initials: V
authors.lastname: Martin
authors.forename: Wojciech
authors.initials: W
authors.lastname: Najbar
authors.forename: Sylvie
authors.initials: S
authors.lastname: Gueguen
authors.forename: Dominique
authors.initials: D
authors.lastname: Grousson
authors.forename: Hyone-Myong
authors.initials: HM
authors.lastname: Eun
authors.forename: Bernard
authors.initials: B
authors.lastname: Lebreux
authors.forename: André
authors.initials: A
authors.lastname: Aubert
mesh_terms: D000818:Animals; D001831:Body Temperature / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003681:Dehydration / Q000628:therapy / Q000662:veterinary / Q000821:virology; D004283:Dog Diseases / Q000188:drug therapy* / Q000401:mortality / Q000821:virology; D004285:Dogs; D004311:Double-Blind Method; D004751:Enteritis / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary* / Q000821:virology; D004906:Erythrocyte Count / Q000662:veterinary; D005243:Feces / Q000821:virology; D005260:Female; D006400:Hematocrit / Q000662:veterinary; D007370:Interferon Type I / Q000627:therapeutic use*; D007958:Leukocyte Count / Q000662:veterinary; D008297:Male; D010322:Parvoviridae Infections / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary* / Q000821:virology; D017993:Parvovirus, Canine; D013047:Specific Pathogen-Free Organisms
chemical_list: D007370:Interferon Type I